Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACR Appropriateness Criteria® Preprocedural Chest or Cardiac Imaging for Cardiothoracic Surgery.

Journal of the American College of Radiology : JACR·2026
Same author

Current State of Fibrotic Interstitial Lung Disease Imaging.

Radiology·2025
Same author

Response to Letter "Towards Objective and Sustainable Outcomes in Women-Focused Faculty Development Programs".

Academic radiology·2025
Same author

ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients: 2024 Update.

Journal of the American College of Radiology : JACR·2025
Same author

Launching a Women-Focused Faculty and Trainee Development Program.

Academic radiology·2025
Same author

ACR Appropriateness Criteria® Tracheobronchial Disease.

Journal of the American College of Radiology : JACR·2024
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers
09:15

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers

Published on: July 19, 2024

Pleural effusions due to dasatinib.

Anupama G Brixey1, Richard W Light

  • 1Vanderbilt University Medical Center, Tennessee 37232, USA. anupama.brixey@vanderbilt.edu

Current Opinion in Pulmonary Medicine
|April 9, 2010
PubMed
Summary
This summary is machine-generated.

Dasatinib, used for leukemia, can cause pleural effusions. Incidence decreased with once-daily dosing, and effusions are manageable without stopping treatment.

More Related Videos

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
03:32

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers
09:15

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers

Published on: July 19, 2024

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
03:32

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

Area of Science:

  • Oncology
  • Pharmacology
  • Pulmonology

Background:

  • Dasatinib is a tyrosine-kinase inhibitor for BCR-ABL positive chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL).
  • Pleural effusions are a frequent complication of dasatinib therapy.
  • Understanding risk factors and management is crucial for patient care.

Purpose of the Study:

  • To review risk factors for dasatinib-associated pleural effusions.
  • To characterize the pleural fluid in these cases.
  • To discuss potential mechanisms and management strategies.

Main Methods:

  • Review of available evidence on dasatinib-associated pleural effusions.
  • Analysis of incidence, fluid characteristics, and contributing factors.
  • Evaluation of current management recommendations.

Main Results:

  • The incidence of pleural effusions with dasatinib is approximately 20%, decreasing with once-daily dosing.
  • Effusions are typically lymphocyte-predominant exudates.
  • Potential mechanisms include immune-mediated pathways or off-target inhibition.

Conclusions:

  • Dasatinib is effective for refractory CML and ALL.
  • Pleural effusions are a complication, but incidence is reduced with once-daily dosing.
  • Management strategies allow continued dasatinib therapy in most cases.